Early Weight-Bearing After the Lapiplasty Mini-Incision Procedure (Mini3D)

Hallux Valgus Clinical Trial

— Mini3D  

Official title:

Prospective Clinical StuDy of Tri-planar Tarsometatarsal (TMT) ArthroDesis With Early Weight-Bearing After Lapiplasty® ProceDure Through a Mini-Incision™ Approach (Mini3D)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05082012
• Other study ID #: CP2021-1
• Status: Terminated
• Phase: N/A
• Start date: September 17, 2021
• Est. completion date: May 9, 2024

Study information

• Verified date: June 2024
• Source: Treace Medical Concepts, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, multicenter, unblinded study to evaluate outcomes of the Lapiplasty® Procedure using the Lapiplasty® Mini-Incision™ System for patients in need of hallux valgus surgery.

Up to 200 subjects will be treated in this study at up to 20 clinical sites. Patients 14 years through 58 years with symptomatic hallux valgus will be eligible to participate based on the inclusion and exclusion criteria defined in the study protocol.

Description:

Prospective, multicenter, unblinded study to evaluate outcomes of the Lapiplasty® Procedure using the Lapiplasty® Mini-Incision™ System for patients in need of hallux valgus surgery:

1. To determine radiographic recurrence of hallux valgus and the timing of failure following hallux valgus correction with the Lapiplasty® Procedure.

2. To determine whether the Lapiplasty® Procedure effectively corrects anatomical alignment of the 1st metatarsal and sesamoids in all three planes.

3. To assess whether early weight-bearing after the Lapiplasty® Procedure affects the union rates or causes loss of 3-plane correction.

4. To evaluate the quality of life and pain scores following the Lapiplasty® Procedure.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 123
• Est. completion date: May 9, 2024
• Est. primary completion date: May 9, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 14 Years to 58 Years

Eligibility

Inclusion Criteria:

Patients satisfying the following criteria will be considered the screening population and will be eligible for participation:

1. Male and females between the ages 14 and 58 years at the time of consent;

2. Closed physeal plates at the time of consent;

3. Intermetatarsal angle is between 10.0° - 22.0°;

4. Hallux valgus angle is between 16.0° - 40.0°;

5. Willing and able to adhere to early weight-bearing instructions post-operatively;

6. Capable of completing self-administered questionnaires;

7. Acceptable surgical candidate, including use of general anesthesia;

8. Female patients must be of non-child bearing potential or have a negative pregnancy test within 7 days prior to index procedure;

9. Willing and able to schedule index procedure within 3 months of consent and able to return for scheduled follow-up visits;

10. Willing and able to provide written informed consent.

Exclusion Criteria:

Patients satisfying the following criteria will not be eligible for participation:

1. Previous surgery for hallux valgus on operative side;

2. Previous surgeries on operative foot involving fusion of foot or ankle joints (other than hammertoe or lesser toes/digits);

3. Additional concomitant procedures outside of the 1st ray;

4. Moderate or Severe osteoarthritis of the MTP joint based on radiographic imaging (including lack of evident crista) or positive grind test;

5. Symptomatic flatfoot or asymptomatic flatfoot (defined as calcaneal inclination <5°and talonavicular subluxation/uncovering >50%);

6. BMI >40 kg/m²;

7. Current nicotine user, including current use of nicotine patch;

8. Current clinical diagnosis of diabetes with fasting plasma glucose > 126 mg/dL and/or HbA1c =7.0;

9. Current clinical diagnosis of peripheral neuropathy or by assessment on 4-point monofilament test;

10. Current clinical diagnosis of fibromyalgia;

11. Current clinical diagnosis of Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy (CRPS/RSD);

12. Current uncontrolled hypothyroidism;

13. Previously sensitized to titanium;

14. Currently taking oral steroids or rheumatoid biologics;

15. Currently taking immunosuppressant drugs;

16. Insufficient quantity or quality of bone to permit stabilization, conditions that retard healing (not including pathological fractures) and conditions causing poor blood supply such as peripheral vascular disease;

17. Active, suspected or latent infection in the affected area;

18. Use of synthetic or allogenic bone graft substitutes;

19. Current diagnosis of metatarsus adductus (defined as MAA = 23°);

20. Known keloid and hypertrophic scar forming;

21. Scheduled to undergo a same-day bilateral procedure. Patient agrees to refrain from the Lapiplasty® Procedure (or other hallux valgus procedures) on contralateral foot for minimum of 6 months post index procedure;

22. Patient has previously been enrolled into this study for a contralateral procedure;

23. Scheduled for any concomitant procedure that would alter patient's ability to early weight-bear post-procedure;

24. Patient requires an incision >4.0 cm to complete the procedure (determined pre-operatively or intra-operatively);

25. Patient is actively involved with a workman's compensation case or is currently involved in litigation;

26. Patient is currently or has participated in a clinical study in the last 30 days prior to signing informed consent or is considering participation in another research protocol during this study. Exceptions to this include survey clinical studies with no treatment or if subject is greater than 12 months post procedure in the Treace ALIGN3D™ study without ongoing protocol defined AE; these are not exclusionary;

27. Patient has a condition or finding that, in the opinion of the Investigator, may jeopardize the patient's well-being, the soundness of this clinical study, or could interfere with provision of informed consent, completion of tests, therapy, or follow-up.

Related Conditions & MeSH terms

• Bunion
• Hallux Valgus

Intervention

Device:
• Treatment of Hallux Valgus
Patients 14 years through 58 years with symptomatic hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated subject duration will be 2 years post index procedure.

Locations

Country	Name	City	State
United States	DOC - Decatur Orthopaedic Clinic	Decatur	Alabama
United States	Stonebriar Foot and Ankle	Frisco	Texas
United States	DOC - Decatur Orthopaedic Clinic	Hartselle	Alabama
United States	JCMG - Podiatry	Jefferson City	Missouri
United States	Foot & Ankle Associates of North Texas - Keller	Keller	Texas
United States	Desert Orthopaedic Center	Las Vegas	Nevada
United States	Orlando Foot and Ankle Clinic - Waterford Lakes Office	Orlando	Florida
United States	University of Pennsylvania / Penn Medicine	Philadelphia	Pennsylvania
United States	Sports Medicine Associates of San Antonio	San Antonio	Texas
United States	Phoenix Foot and Ankle Institute	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Treace Medical Concepts, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Radiographic Recurrence	To determine radiographic recurrence of hallux valgus and the timing of failure following hallux valgus correction with the Lapiplasty® Procedure	24 months
Secondary	Radiographic Angular/Positional Alignment	Change in radiographic angular/positional alignment before/after the Lapiplasty® Procedure	pre-op, 6 weeks, 4 months, 6 months, 12 months, 24 months post Lapiplasty® Procedure
Secondary	Radiographic Healing	Union vs non-union -- Non-union defined as lucency at TMT joint, hardware failure and/or loss of correction, plus clinical pain at first TMT joint	12 months post Lapiplasty® Procedure
Secondary	Clinical complications due to Lapiplasty® System Implants, the procedure, the post-op weight-bearing protocol or health conditions that could affect other outcome measures - measured by Adverse Events and Product Complaint data	Clinical complications due to Lapiplasty® System Implants, the procedure, the post-op weight-bearing protocol or health conditions that could affect other outcome measures - measured by Adverse Events and Product Complaint data	24 months post Lapiplasty® Procedure
Secondary	Time to start weight-bearing in a boot	Time to start weight-bearing in a boot	0-3 weeks, post Lapiplasty® Procedure
Secondary	Time to start weight-bearing in a shoe	Time to start weight-bearing in a shoe	6 weeks, post Lapiplasty® Procedure
Secondary	Time to return to full unrestricted activity	Time to return to full unrestricted activity	6 weeks - 6 months, post Lapiplasty® Procedure
Secondary	Change in Pain	Change in pain assess via Visual Analog Scale (VAS)	0-2 weeks, 2-3 weeks, 6 weeks, 4 months, 6 months, 12 months, 24 months post Lapiplasty® Procedure
Secondary	Change in Quality of Life	Change in quality of life via PROMIS-29, PROMIS-25, MOxFQ	6 months, 12 months, 24 months post Lapiplasty® Procedure
Secondary	Change in Range of Motion	1st MTP dorsiflexion and plantarflexion	12 months, 24 months post Lapiplasty® Procedure
Secondary	Change in Radiographic Foot Length	Change in radiographic foot length compared to baseline visit	12 months post Lapiplasty® Procedure
Secondary	Change in Radiographic Foot Width	Change in radiographic foot width compared to baseline visit	12 months post Lapiplasty® Procedure
Secondary	Change in Swelling at Foot, Ankle & Mid-Calf (Circumference)	Change in swelling as compared to 0-2 week visit	6 weeks and 4 months post Lapiplasty® Procedure
Secondary	Change in Scar Quality as Measured by Patient and Observer Scar Assessment Scale (POSAS)	Change in scar quality in comparison to baseline visit	4 months, 6 months, and 12 months post Lapiplasty® Procedure